Mumbai, India, February 3, 2023: Lupin Life, the Consumer Healthcare division of Lupin, today announced the first-ever Aptivate Champion Run for Kids on February 12, 2023, at MMRDA Grounds, Bandra Kurla Complex, Mumbai. The Aptivate Champion Runwillencourageparents and children to together improve children’s health and well-being through physical activity andbetter appetite.
The Aptivate Champion Run offers three categories of run for children, including a 500-meter run for 4-7-year-olds preferably with their parents, a 1.5-kilometer timed run for 8-10-year-olds, and a 2.5-kilometer timed run for 11-13-year-olds. At the conclusion of the event, all participants will be given certificates and medals as a symbol of their accomplishment.Post-run there will be other activities such as trampolines, bouncy castles, toy trains, zumbasessions and more to celebrate the event. Neha Dhupia, an actress, TV personality and a mother of two children, will officially flag off the event and hand over trophies to the winners.
Through this important initiative, Lupin Life encourages children from Mumbai, Thane,and Navi Mumbai to participate in the Aptivate Champion Run. Lupin’s Aptivate syrup helps children enhance their health and overall well-being by naturally boosting their appetite. This formulation, created from 100% Ayurvedic ingredients like amla, giloy and pippali improves immunity and naturally increases energy levels in children.
Commenting on the announcement, Rajeev Sibal, President – India Regional Formulations, Lupin said, “The Aptivate Champion Run for Kids is more than just a run. It is a celebration of our commitment to the health and well-being of children. Through this run, we hope to inspire children to lead healthier lives and strengthen their immunity through the joy of physical activity and running. We invite parents to join their children in this fun and meaningful event, andin showing their support for our mission.”
Register for the Aptivate Champion Run for kids here.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
For further information or queries please contact –
Vice President & Global Head – Corporate Communications